Clinical OMICS

SEP-OCT 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1023557

Contents of this Issue

Navigation

Page 45 of 51

44 Clinical OMICs September/October 2018 www.clinicalomics.com Gleaning health and wellness data from 1 million or more Americans is the goal of the NIH's All of Us Research Program, which opened for national enrollment on May 6. People ages 18 and older are eligible to enroll, regard- less of health status. Those who enroll join more than 25,000 participants who signed up for All of Us during a beta phase. In addition to enrolling 1 million-plus participants, All of Us aims to become the nation's largest and most diverse research cohort, with plans to oversample communities underrepresented in past research. Eric Dishman, a kid- ney cancer survivor who directs All of Us, told the website FiveThirtyEight the program aims to have 70% to 75% of its data contributed by underrepresented people, including women and people of color. To generate genotype and whole genome sequence data, the NIH plans to fund up to two genome centers in the cur- rent federal fiscal year, which ends September 30. Each cen- ter is expected to spend up to $15 million in the first year, when both centers are to generate and analyze data from 100,000 participants. That number rises to 200,000 partici- pants annually in years 2 through 5. All of Us participants will also share health and lifestyle information, collected from online surveys and data from electronic health records (EHRs). The surveys are designed to learn more about participants' overall health and habits and where they live and work. The EHR data will information related to medical histories, treatment effective- ness, and side effects. All of Us is a component of the Preci- sion Medicine Initiative (PMI), launched in the 2016 fiscal year when $130 mil- lion was allocated to NIH to build a national cohort, and $70 million was allocated to the NIH's National Cancer Institute to lead efforts in cancer genomics as part of PMI for Oncology. The NIH has drawn upon more than 100 organizations to carry out the research program. All of Us Research Program UNITED STATES lion over five years for the King Abdulaziz City for Science and Technology (KACST)—the agency charged with sup- porting scientific research—toward the Program. KACST joined Life Technologies (since acquired by Thermo Fisher Scientific) in launching the program in 2013. Soon after, the price of oil fell globally, leading to reported delays in fund- ing the project. Yet progress has been made. As of the end of 2016, according to KACST, the Saudi Human Genome Pro- gram has developed 13 gene panels covering more than 5,000 inherited diseases, and sequenced more than 10,000 samples from Saudi patients with inherited diseases that resulted in identification of more than 2,000 variants underlying the diseases—including more than 500 "Saudi mutations" represented in multiple patients. Saudi-spe- cific mutations alone cost the Kingdom SR 6.4 billion ($1.7 billion) annually. (continued from previous page) jxfzsy/ Getty Images Liana Monica Bordei / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - SEP-OCT 2018